RESUMO
We report our experience of allogeneic peripheral blood stem cell transplantation using non-myeloablative conditioning regimens delivered and supported on an outpatient basis. A group of 44 patients underwent 47 allograft procedures using peripheral blood stem cells. Approximately one third of the individuals did not require red blood cells transfusions: the median of transfused red blood cells units was 1 (range 0-10). In addition one out of three did not require platelet transfusions either, the median of platelet transfusions being 1 (range 0-6). In fourteen allografts (30%) neither red blood cells nor platelet transfusions were used. An inverse correlation was found between the number of CD34 cells infused and the PRBC and PLT transfusion requirements, those patients receiving high numbers of CD34 cells needing fewer transfusions of both PRBC and platelets. The possibility of conducting allografts without transfusion of blood products in some patients may result in a decrease in both cost and the risks stemming from exposure to human blood derivatives.
Assuntos
Transfusão de Eritrócitos/estatística & dados numéricos , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco de Sangue Periférico , Transfusão de Plaquetas/estatística & dados numéricos , Condicionamento Pré-Transplante/métodos , Vidarabina/análogos & derivados , Adolescente , Adulto , Bussulfano , Criança , Pré-Escolar , Ciclofosfamida , Ciclosporina , Feminino , Filgrastim , Fator Estimulador de Colônias de Granulócitos , Mobilização de Células-Tronco Hematopoéticas , Humanos , Masculino , Metotrexato , Pessoa de Meia-Idade , Neoplasias/terapia , Transplante de Células-Tronco de Sangue Periférico/estatística & dados numéricos , Estudos Prospectivos , Proteínas Recombinantes , Transplante HomólogoRESUMO
UNLABELLED: Cancer is a very important national health problem in Mexico, while a significant increase in the total and childhood cancer mortality has been recorded during the last decades. Chemoprevention, defined as the use of natural or synthetic agents to prevent or to block the development of cancer in human beings, is a new and promising strategy in the battle against cancer. Saffron, obtained from the dried red-dark stigmas of Crocus sativus L., an important spice rich in carotenoids, is commonly consumed in different parts of the world and used as a medical drug to treat numerous diseases. OBJECTIVE: To test the toxicity of saffron extract in vivo; to separate different ingredients in saffron extracts; to examine the cytotoxic effect of saffron and its main components on the growth of different human malignant cells in vitro; to evaluate the mutagenic and antimutagenic activities of saffron extract. METHODS: HPLC with photodiode-array detection was used for semi-preparative separation of different ingredients of saffron crude extract. Colony formation assay was used to determinate the cytotoxic activity of saffron extract and its components on human tumor cells in vitro. Mutagenicity and antimutagenicity assays were performed by the Ames method. RESULTS: Saffron is not toxic, non-mutagenic, non-antimutagenic and non-comutagenic. Twelve components were isolated: crocin-1, crocin-2, crocin-3, picrocroein, acid form of picrocrocin, HTCC-diglycosil-kaempferol trans-crocin-4, trans-crocin-2, trans-crocin-3, safranal, crocetin and cis-crocin-3. Saffron extract itself and some of its ingredients displayed a dose-dependent inhibitory activity against different types of human malignant cells in vitro. HeLa cells were more susceptible to saffron than other tested cells. CONCLUSIONS: Taken together, our results and literature data indicate that saffron could be used as a potential cancer chemopreventive agent in clinical trials.